EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Effect of Recombinant Erythropoietin on the Levels of Hemoglobin, Mean Corpuscular Volume, LDH, and Length of Stay at the Hospital in COVID-19 Patients

HamidReza Samimagham, Mehdi Hassaniazad, Dariush Hooshyar, Maryam Haddad, Mohsen Arabi, Mitra Kazemi Jahromi

Journal of Kermanshah University of Medical Sciences · 2022

DOI: 10.5812/jkums-126623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Kermanshah University of Medical Sciences, 2022. Verfasst von HamidReza Samimagham und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Erythropoietin plays a significant role in the growth of red blood cells, hemoglobin levels, and tissue oxygenation in critically ill patients, as well as anti-inflammatory and neuroprotective effects.

Objectives

This study aimed to evaluate the effect of recombinant erythropoietin on improving COVID-19 patients.

Methods

This study was conducted on 20 COVID-19 participants with hemoglobin of ≥ 9. The inclusion criteria was at least one severe COVID-19 symptom/sign in this interventional study. The primary outcome was a combination of hospital stay length and paraclinical evaluation (LDH and hemoglobin level). The outcomes and side effects were evaluated on day 0 (before the intervention) and five (post-intervention).

Results

The mean hemoglobin level was 10 ± 1.1 gr/dL in the intervention group and 8 ± 0.7 gr/dL in the control group post-treatment, indicating a significant difference between the groups (P = 0.04). The mean hospital stay length (6 ± 2 days) in the intervention group was significantly less than the control group (9 ± 4 days) (P = 0.001). At the end of the treatment, the mean LDH was significantly lower in the intervention group (503 ± 264 µ/L) than in the control group (725 ± 320 µ/L; P = 0.017).

Conclusions

According to the results, this study provides the first solid evidence for the positive effects of recombinant erythropoietin on COVID-19.

Zitieren

APA

Samimagham, H., Hassaniazad, M., Hooshyar, D., Haddad, M., Arabi, M., & Jahromi, M. K. (2022). The Effect of Recombinant Erythropoietin on the Levels of Hemoglobin, Mean Corpuscular Volume, LDH, and Length of Stay at the Hospital in COVID-19 Patients. Journal of Kermanshah University of Medical Sciences. https://doi.org/10.5812/jkums-126623

Vancouver

Samimagham H, Hassaniazad M, Hooshyar D, Haddad M, Arabi M, Jahromi MK. The Effect of Recombinant Erythropoietin on the Levels of Hemoglobin, Mean Corpuscular Volume, LDH, and Length of Stay at the Hospital in COVID-19 Patients. Journal of Kermanshah University of Medical Sciences. 2022. doi:10.5812/jkums-126623

BibTeX
@article{Samimagham2022,
  author = {Samimagham, HamidReza and Hassaniazad, Mehdi and Hooshyar, Dariush and Haddad, Maryam and Arabi, Mohsen and Jahromi, Mitra Kazemi},
  title = {The Effect of Recombinant Erythropoietin on the Levels of Hemoglobin, Mean Corpuscular Volume, LDH, and Length of Stay at the Hospital in COVID-19 Patients},
  journal = {Journal of Kermanshah University of Medical Sciences},
  year = {2022},
  doi = {10.5812/jkums-126623}
}
Kostenlos starten →